Feb 22, 2008
Updated Data on the Use of ThermoDox® in Patients with Recurrent Chest Wall Breast Cancer will be Presented at the 10th International Congress on Hyperthermic Oncology in Munich
COLUMBIA, Md., Feb 22, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) today announced that Dr. Ellen Jones, a Radiation Oncologist at Duke Medical Center, has been invited to present updated interim data from the current ThermoDox® study involving patients with Recurrent Chest Wall Breast Cancer (RCW) at the 10th International Congress on Hyperthermic Oncology. The meeting, held in association with the European Society of Hyperthermic Oncology, The Society of Thermal Medicine and The Asia Society of Hyperthermic Oncology, will take place in Munich, Germany in April 2008. Dr. Jones will present preliminary safety and clinical activity data derived from the current RCW study being conducted at Duke Medical Center.
The RCW study was previously reviewed at last years meeting in Prague where Dr. Jones presented safety data on the use of ThermoDox in conjunction with mild hyperthermia at the chest wall. The data presented last year suggested that ThermoDox was safe and demonstrated clinical activity at the 30mg/m2 dose level. Since then further patients have been enrolled at both 30mg/m2 and 40mg/m2 doses.
Mr. Michael Tardugno, Celsion's President and Chief Executive Officer, commented, "The preliminary data presented last year provided a degree of optimism for the use of ThermoDox in this patient population. We are very pleased that new data from the study will be presented at this years meeting. We are on track to determine a safe dose for ThermoDox in this patient population before the end of the year. This dose will be used in a study designed to obtain pivotal data for use in submission to the FDA for an approval to treat this group of patients who have few other options."
About ThermoDox: ThermoDox is Celsion's proprietary heat-sensitive liposomal encapsulation of doxorubicin, an approved and frequently used anti-cancer drug used in the treatment of various cancers including breast cancer. Localized mild hyperthermia (40-42 degrees Celsius) releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.
Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, North Shore Long Island Jewish Health System. Additional information about Celsion Corporation can be found on the Celsion website at www.celsion.com.
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
SOURCE: Celsion Corporation
Paul G. Henning, 212-554-5462
Copyright Business Wire 2008
News Provided by COMTEX